Brian Lindenmayer, MD
Sports Medicine · Gonzales, LANPI 1790983807
Payments from drug & device makers
Across 974 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- GSK$1K
- Novo Nordisk$1K
- Lilly USA, LLC$730
- Pfizer$695
- Boehringer Ingelheim$690
- plus $7K from 50 others
What the payments were for
- Food & beverage$13,88799%
- Education$1081%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edarbyclor$155
- SYMBICORT$107
- BYDUREON$107
- FARXIGA$107
- Ozempic$101
How this compares
$14,054 in reported general payments places this provider in the 75th percentile of 82 sports medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 210 | $232,706 |
| OzempicSemaglutide | 108 | $133,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $70,220 |
| TrulicityDulaglutide | 49 | $59,962 |
| JardianceEmpagliflozin | 59 | $56,202 |
| EliquisApixaban | 56 | $49,457 |
| LinzessLinaclotide | 39 | $46,074 |
| Xtampza ErOxycodone Myristate | 46 | $39,468 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,167 | $33,779 |
| XareltoRivaroxaban | 39 | $33,068 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 745 | $32,974 |
| FarxigaDapagliflozin Propanediol | 32 | $25,077 |
| MyrbetriqMirabegron | 38 | $23,249 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $21,744 |
| Spiriva RespimatTiotropium Bromide | 40 | $21,539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $730 | $292,668259 claims |
| Novo NordiskOzempic | $1,223 | $133,845108 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Tradjenta, Glyxambi | $690 | $130,508165 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,228 | $77,99797 claims |
| PfizerEliquis, Lyrica, Premarin | $695 | $65,98085 claims |
| AbbVieLinzess | $2,442 | $46,07439 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $432 | $39,46846 claims |
| Johnson & JohnsonXarelto | $457 | $33,06839 claims |
| MerckJanuvia, Belsomra | $405 | $29,99442 claims |
| AstraZenecaFarxiga | $286 | $25,07732 claims |
| Astellas Pharma US IncMyrbetriq | $658 | $23,24938 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $516 | $21,15328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 82 sports medicine providers in Louisiana.
Other sports medicine in Gonzales
- Felix SavoieNew Orleans$1.4M
- Misty SuriNew Orleans$1.2M
- Michael ObrienNew Orleans$396K
- Jeremy BurnhamBaton Rouge$120K
- Brett CascioLake Charles$88K
- Brian GodshawNew Orleans$69K
- Andrew GottschalkJefferson$45K
- Michael LeddyAlexandria$44K
- Steven JonesHammond$38K
- Mario Lobao GoncalvesShreveport$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.